#### Edgar Filing: INNOVUS PHARMACEUTICALS, INC. - Form 3

INNOVUS PHARMACEUTICALS, INC.

Form 3 April 24, 2017

### FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response...
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement INNOVUS PHARMACEUTICALS, INC. [INNV] Gutierrez Rauly (Month/Day/Year) 04/24/2017 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 9171 TOWNE CENTRE DRIVE, (Check all applicable) SUITE 440 (Street) 6. Individual or Joint/Group 10% Owner Director Officer Other Filing(Check Applicable Line) (give title below) (specify below) \_X\_ Form filed by One Reporting Vice President, Finance Person SAN DIEGO, CAÂ 92122 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	,	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I)	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(Instr. 5)

Restricted Stock Unit (1)	(2)	(2)	Common Stock	1,250,000	\$ <u>(2)</u>	D	Â
Restricted Stock Unit (1)	(3)	(3)	Common Stock	500,000	\$ <u>(3)</u>	D	Â

#### **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Gutierrez Rauly 9171 TOWNE CENTRE DRIVE, SUITE 440 SAN DIEGO. CA 92122	Â	Â	Vice President, Finance	Â		

## **Signatures**

/s/ Rauly
Gutierrez

\*\*Signature of Reporting Person

O4/24/2017

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each RSU represents a contingent right to receive 1 share of the issuer's common stock upon settlement.
- RSU was granted on September 23, 2016 under the Amended and Restated 2016 Equity Incentive Plan (the "2016 Plan"). 312,500 RSUs (2) vest on September 23, 2017; the total remaining shares vest in eight (8) pro rata equal installments, quarterly for two (2) years thereafter, subject to continued service.
- (3) RSU was granted on April 24, 2017 under the 2016 Plan. 166,666 RSUs vest on April 24, 2018; the total remaining shares vest in eight (8) pro rata equal installments, quarterly for two (2) years thereafter, subject to continued service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2